The Separate and Combined Glucagonotropic Effects of Glucose-dependent Insulinotropic Polypeptide and Alanine in Subjects With and Without Type 1 Diabetes

NAEnrolling by invitationINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

November 15, 2025

Study Completion Date

December 31, 2025

Conditions

Type 1 Diabetes

Interventions

DRUG

Glucose-dependent Insulinotropic Polypeptide (GIP)

GIP

DRUG

alanine

Alanine

DRUG

Saline (NaCl 0,9 %) (placebo)

Placebo

Trial Locations (1)

Gentofte Hospital, Hellerup

All Listed Sponsors

lead

Asger Lund, MD

OTHER